argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
28 apr 2016 - 11:08
Statutaire naam
argenx SE
Titel
argenx announces results of Annual General Meeting 2016
Bericht
Breda, the Netherlands / Ghent, Belgium - argenx N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that all resolutions presented at the Company's Annual General Meeting were duly passed at the meeting, which was held today at 09:00 CET.
Datum laatste update: 28 juli 2024